Darolutamide may offer greater benefits than enzalutamide or apalutamide for Black and White patients with non-metastatic ...

Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...

She noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...

Patients with HRR-deficient metastatic castration-resistant prostate cancer experienced a 14-month gain in OS and a 38% lower ...

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...

Key contributors to PrCa progression include genetic mutations, elevated androgen receptor expression ... advance to castration-resistant PrCa (CRPC), presenting a significant therapeutic hurdle.

Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient ...

Key contributors to PrCa progression include genetic mutations, elevated androgen receptor expression ... advance to castration-resistant PrCa (CRPC), presenting a significant therapeutic hurdle.

The understanding of the biology of CRPC and the evidence that CRPC still remains driven by androgen receptor signaling led to the discovery of new therapeutic targets. In the last few years ...

Pomerantz LLP announces that a class action lawsuit has been filed against ESSA Pharma Inc. ("ESSA" or the "Company") and certain officers.  The class action, filed in the United States District Court ...

The optimistic assessment of the revenue potential for androgen receptor inhibitor Nubeqa (darolutamide ... castration-resistant prostate cancer (CRPC), but expansion into hormone-sensitive ...